<DOC>
	<DOCNO>NCT02075073</DOCNO>
	<brief_summary>The purpose study compare pharmacokinetics , safety , tolerability immunogenicity SB3 Herceptin® ( EU source Herceptin® US source Herceptin® ) healthy male subject .</brief_summary>
	<brief_title>Pharmacokinetic , Safety , Tolerability Immunogenicity Study SB3 Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Healthy male subject Have body weight 60.0 94.9 kg body mass index 18.0 29.9 kg/m² , inclusive . history and/or current clinically significant gastrointestinal , renal , hepatic , cardiovascular , haematological ( include pancytopenia , aplastic anaemia blood dyscrasia ) , pulmonary , neurologic , metabolic ( include know diabetes mellitus ) , psychiatric significant allergic disease exclude mild asymptomatic allergy . history and/or current cardiac disease previously receive monoclonal antibody fusion protein . history cancer include lymphoma , leukaemia skin cancer . Have receive live vaccine ( ) within 30 day prior Screening require vaccine ( ) Screening End Study visit . intake medication halflife &gt; 24 h within 1 month 10 halflives medication prior administration investigational product .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Pharmacokinetics</keyword>
</DOC>